Running Head: Poor CD4 + T-cell recovery in HIV patients on ART
INTRODUCTION
Despite control of HIV replication following treatment with effective antiretroviral therapy (ART), many patients fail to normalize CD4 + T-cell numbers. Approximately 40% of patients commencing therapy with fewer than 200 CD4 + T-cells/µL have less than 500 CD4 + T cells/µl after 10 years on ART 1 . This scenario is associated with a higher rate of mortality and morbidity 2 , which includes atherosclerotic vascular disease 3, 4 , osteoporosis and fractures 5 and non-AIDS-defining cancers 6-8 .
Persistent CD4 + T cell deficiency may reflect damage to the thymus that impairs its regeneration [9] [10] [11] , persistent immune activation 12, 13 , fibrosis of lymphoid tissue 14, 15 and/or failure to regenerate T-cells via peripheral homeostatic mechanisms. The latter of these may result from a reduced capacity of naïve T-cells to proliferate following stimulation 16 . Homeostatic maintenance of naïve T-cells is regulated by interleukin (IL)-7 and/or T-cell receptor (TCR) ligation 17, 18 . We have shown that defects of IL-7 signaling in HIV patients with persistent CD4 + T-cell deficiency despite effective ART are associated with CD4 + T-cell activation and senescence 19 . Similarly, the capacity for naïve T-cells to proliferate following TCR engagement may also be impaired in treated HIV disease [20] [21] [22] [23] . This may reflect poor signaling downstream of the TCR and its associated costimulatory molecules, CD27 and CD28. Indeed, HIV infection (regardless of treatment status) is characterized by aberrant expression of CD27 and CD28 on T-cells 20 .
CD27 and CD28 act in concert with the TCR to support T-cell expansion 24 . CD27 provides costimulatory signals for naïve CD4 + T-cells, and expression is transiently increased on the cell surface following TCR stimulation 25 . This is important in antigen-specific memory T-cell formation 26 and Tcell survival after activation 24 . CD28 promotes assembly of the T-cell signaling complex and amplifies 4 signals received by the TCR, thereby decreasing the threshold required for T-cell expansion 27 . CD28
signaling also promotes IL-2 production, enhancing cell cycle activity and the survival of activated Tcells 28 .
Here, we investigate whether defects in anti-CD3 mediated stimulation of proliferation and regulation of CD27 and CD28 expression associate with poor CD4 + T-cell recovery in HIV patients responding to
ART. This is assessed here in total, naïve and CD31 
MATERIALS AND METHODS

Study population
Thirty-nine adult HIV-1-infected patients (2 females, 37 males), attending clinics at Royal Perth Hospital, Western Australia, participated in the study. All patients were receiving ART, defined as treatment with at least three antiretroviral drugs. Criteria for inclusion were nadir CD4 + T-cell counts <100/μL, ART for >12 months and undetectable plasma HIV RNA for >6 months. Patients were categorized as having normal (n=20) or low (n=13) CD4 + T-cell counts based on values >500 or <350 CD4 + T-cells/µL, respectively. For correlations between the parameters measured, additional patients (6 males) with intermediate CD4 + T-cell counts (350-500 CD4 + T-cells/µL) were included for all correlations. The healthy control cohort comprised 10 adults (4 females, 6 males) aged 22 to 54 years.
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Informed consent was obtained from all participants and the study was approved by the Human
Research Ethics Committees of Royal Perth Hospital and the University of Western Australia.
HIV-1 RNA viral load
Plasma HIV RNA levels were assayed by quantitative reverse transcription polymerase chain reaction (Amplicor TM Version 1.5, Ultrasensitive Protocol, 50-75000 copies/mL) (Roche Diagnostic Systems, Branchburg, New Jersey, USA).
T-cell phenotyping
Total, naïve and memory CD4 + and CD8 + T-cells were enumerated in EDTA-treated whole blood using the following fluorescently conjugated monoclonal antibodies (mAbs); CD45-APC-H7, CD3-PerCP, CD4-APC, CD8-PeCy7, CD45RA-FITC and CD62L-PE (BD Biosciences, San-Jose, California, USA).
Peripheral blood mononuclear cells (PBMC) were separated from lithium heparin-treated whole blood by Ficoll-Paque density centrifugation and cryopreserved in 10% dimethylsulphoxide/90% heat inactivated fetal calf serum. To assess CD27 and CD28 expression, thawed PBMC were incubated with CD3-V450, CD4-V500, CD45RA-APC-H7, CD27-PerCP-Cy5. minimum of 100 000 lymphocyte events per sample were analyzed using FlowJo software (Tree Star, Ashland, Oregon, USA).
Proliferation assay (Ki67 expression)
Thawed PBMC were cultured at 10 6 cells/mL in RPMI/10% FCS, with or without 10ng/mL anti-CD3
antibody (Mabtech, Nacka Strand, Stockholm SE, Sweden) at 37ºC for 5 days. Cells were then surface stained with the following fluorescently conjugated mAbs from BD Biosciences: CD3-V450, CD4-V500, CD45RA-APC-H7, CD27-PerCP-Cy5.5, CD28-APC and CD31-PE. Intracellular staining using Ki67-FITC was then performed using the Human FoxP3 Buffer Set (BD Biosciences) according to the manufacturer's protocol.
Statistical analysis
Statistical analyses were performed with GraphPad Prism version 5.01 (GraphPad Software, San Diego, California, USA), using non-parametric statistics. Mann-Whitney tests were performed for continuous variables and correlation coefficients were determined by the Spearman's rank correlation test. Fisher's exact tests were performed for categorical analyses. For all tests, p<0.05 was considered to represent a significant difference.
RESULTS
Patient groups were well matched
Demographic data are presented in Table 1 . The duration of ART was longer in patients with normal CD4 + T-cell counts (p=0.003), however time on ART did not correlate with proportions of total or 7 naive CD4 + T-cells in an analysis that combined both patient groups (r=0.23-0.24, p=0.14-0.17).
Furthermore, 5 years after study entry, all participants originally classified as having CD4 + T-cell deficiency had <340 CD4 + T-cells/µL after a median time of 12 (range 5-17) years on ART. Hence, our definition of poor recovery of CD4 + T-cell numbers was independent of time on ART in this group of patients.
Proliferation assessed in viable T-cells did not differentiate HIV patients with low or normal CD4 + Tcell counts
CD4
+ T-cell proliferation induced by anti-CD3 was assessed by subtracting the percentages of CD4 + Tcells expressing Ki67 in unstimulated cultures (background proliferation) from the percentages seen after stimulation (ΔKi67). Background proliferation was negligible, with Ki67 expression detected at rates of less than 5% in 90% of individuals. Low lymphocyte viability (absent lymphocyte population on flow cytometry plots; Figure 1 ) precluded analysis of data from some patients. This was more common in patients with low CD4 + T-cell counts than patients with normal CD4 + T-cell counts (54% vs 5%; Fisher's exact test, p=0.003), but could not be ascribed to any of the characteristics described in 
Upregulation of CD27 and CD28 following anti-CD3 stimulation correlates with CD4 + T-cell proliferation
Surface expression of CD27 and CD28 on healthy T-cells increases following TCR activation 20, 25, 30 .
To investigate whether poor CD4 + T-cell recovery in HIV patients is associated with impaired upregulation of these costimulatory molecules following anti-CD3 stimulation, we assessed the proportion of CD27 hi CD28 hi CD4 + T-cells present after stimulation with anti-CD3 for 5 days ( Figure   3A ).
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In samples with viable lymphocytes (low CD4 + T-cells, n=6; normal CD4 + T-cells, n=19), the proportion of CD4 + T-cells that upregulated expression of CD27 and CD28 to a CD27 hi CD28 hi phenotype after anti-CD3 stimulation did not differ between HIV patients with low or normal CD4 + Tcell counts (p=0.48), but were lower in both patient groups compared to healthy controls (p=0.008 and p=0.007, respectively) ( Figure 4A) . In a combined analysis of all patients following stimulation with anti-CD3, induction of CD27 hi CD28 hi expression on total, naïve and CD31 + naïve CD4 + T-cells correlated with Ki67 in total (r=0.56, p=0.002; Figure 4B ), naïve (r=0.46, p=0.02; Figure 4C ) and CD31 + naïve (r=0.41, p=0.03; Figure 4D ) CD4 + T-cells, respectively. In healthy controls, induction of CD27 hi CD28 hi expression on total, naïve and CD31 + naïve CD4 + T-cells also correlated with Ki67 in total (r=0.57, p=0.09; Figure 4E ), naïve (r=0.67, p=0.04; Figure 4F ) and CD31 + naïve (r=0.65, p=0.04; Figure 4G ) CD4 + T-cells, respectively. Figure 3B . In total, naïve and CD31 + naïve CD4 + T-cells, Ki67 expression was greater in cells expressing high levels of CD27 and CD28 ( Figure 3C-E) . This was observed in both HIV patients and healthy controls.
Ki67 expression induced by anti-CD3 was greater in
Baseline expression and upregulation of CD27 and/or CD28 expression after anti-CD3 stimulation correlate inversely with CD4 + T-cell senescence
Finally, we examined the relationship between CD27 and CD28 expression on CD4 + T-cells and markers of CD4 + T-cell activation, senescence and apoptotic potential. As previously demonstrated in this cohort 19, 31 , patients with low CD4 + T-cell counts had higher expression of HLA-DR (p=0.0002), CD57 (p=0.02) and Fas (p=0.01) on total CD4 + T-cells than patients with normal CD4 + T-cell counts.
The proportions of CD4 + T-cells expressing CD27, CD28 and CD27/CD28 at baseline correlated inversely with expression of CD57, HLA-DR and Fas on total CD4 + T-cells [r= -0.47-(-0.72), p<0.0001-0.01] (Table 3) . Similarly, an inverse correlation was evident between the proportion of CD4 + T-cells that upregulated expression to CD27 hi CD28 hi after anti-CD3 stimulation and expression of CD57 on CD4 + T-cells (r= -0.39, p=0.04) ( Table 3 ).
DISCUSSION
Here, we compared CD4 + T-cell proliferation and expression of CD27 and CD28 in response to anti-CD3 stimulation, in HIV patients receiving effective ART categorized as having either low or normal CD4 + T-cell counts, and healthy controls. The levels of proliferation induced by anti-CD3 were similar in all groups, suggesting that CD4 + T-cells from patients with low CD4 + T-cell counts are not defective in their capacity to proliferate. Our ability to detect differences in proliferation across groups may have been impeded by the small number of patients with viable cells, particularly in the low CD4 + T cell group. However, similar findings were observed in this same cohort of HIV patients when proliferative responses to IL-7 were assessed 19 suggesting that what distinguishes this group of patients with low CD4 + T cell counts is that their CD4 + T cells are more prone to apoptosis in culture. In contrast, other studies found that Ki67 expression was induced less efficiently among naïve CD4 + T-cells in HIV patients compared to controls 20, 21 . However, unlike our study, those studies were performed on combined cohorts of treated and untreated HIV patients, with varying viral loads, so the stage of HIV 11 disease (i.e. detectable viraemia) may be a critical factor in those findings. We did however observe a direct correlation between proliferative responses to anti-CD3 or IL-7. Thus, patients with a diminished response to IL-7 also responded poorly to anti-CD3. capacity. In a similar study combining treated and untreated HIV patients, after two days of anti-CD3 stimulation, cells that increased expression of CD27/CD28 were enriched for Ki67 + , whereas Ki67 was rarely expressed in cells that did not increase CD27/CD28 expression 20 . Moreover, addition of soluble anti-CD28 to cultures (with anti-CD3) increased cell cycle entry, even in cells that were only able to weakly upregulate costimulatory molecule expression 20 . Hence, the authors suggest that agents capable of increasing CD27 and CD28 expression on T-cells, or the use of costimulatory agonists, may potentially be useful adjuvants in HIV disease 20 .
Persistent CD4 + T-cell deficiency in HIV patients receiving ART has been linked to chronic activation of the immune system 19, 31, 34 . We observed inverse correlations between CD27 and/or CD28 expression at baseline and markers of T-cell activation, senescence and pro-apoptotic potential.
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Yonkers et al. examined hepatitis C virus (HCV)-infected patients with reduced naïve CD4 + T-cell numbers, and found associations between increased activation and impaired CD27 upregulation, or increased susceptibly to cell death after TCR stimulation 30 . Additionally in our cohort, impaired homeostatic IL-7/IL-7 receptor signaling was associated with activation and senescence of CD4 + Tcells 19 . Accordingly, Bazdar and colleagues reported that IL-7 enhances Ki67 responses to TCR activation in naïve CD4 + T-cells from healthy controls and HIV patients 16 . Therefore, an inability to respond to IL-7 may contribute to poor TCR mediated signaling
The clearest limitation to our study is the low number of patients with CD4 + T-cell deficiency on ART whose cells remained viable after culture. Furthermore as a viability dye was not included, we can not exclude the possibility that non-viable cells were included in the analysis. These results would also need to be validated using purified naive T-cells, as stimulation is likely to modulate expression of CD27 and CD28 and induce differentiation of some naïve T cells into memory cells. Particular strengths of our study were the focus on patients with a nadir CD4 + T-cell count below 100 cells/µL, as low nadir CD4 + T-cell counts are a strong predictor of poor immune reconstitution on ART 35-37 , and our definition of CD4 + T cell deficiency (<350 cells/µL) and normal CD4 + T-cell counts (>500 cells/µL), as these values predict mortality 38 .
In conclusion, our results show decreased expression of CD27 and CD28 on CD4 + T-cells in HIV patients with deficient CD4 + T-cell recovery on ART in association with increased markers of T cells activation and senescence. Furthermore, impaired upregulation of these costimulatory molecules in response to anti-CD3 stimulation was observed in all HIV patients, regardless of immune recovery status and this deficiency was associated with poor proliferative responses to anti-CD3 stimulation and increased markers of T-cell activation and senescence. Therefore, a failure to upregulate CD27 and
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CD28 after TCR engagement may contribute towards the perturbations in naïve T-cell homeostasis that persist in some HIV patients on ART. 
